Why Advanced Biomed Inc.’s (ADVB) Stock Is Down 13.79%
As of Tuesday, April 08, Advanced Biomed Inc.’s ADVB share price has dipped by 13.79%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: Advanced Biomed Inc. (ADVB)
Advanced Biomed Inc. ADVB
$8.62
-1.46
-14.48%
July 31, 2026 12:29:50 PM
EST
Volume: 45,956
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People’s Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Commentary & Analysis
Why Advanced Biomed Inc.’s (ADVB) Stock Is Down 7.93%
As of Tuesday, April 08, Advanced Biomed Inc.’s ADVB share price has dipped by 7.93%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Advanced Biomed Inc.’s (ADVB) Stock Is Down 7.24%
As of Tuesday, April 08, Advanced Biomed Inc.’s ADVB share price has dipped by 7.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Advanced Biomed Inc.’s (ADVB) Stock Is Down 25.17%
As of Tuesday, April 08, Advanced Biomed Inc.’s ADVB share price has dipped by 25.17%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ADVB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $16.7 | $334.8 | 9% |
|
| Shares Out (Mil) | 1.3 | 41.7 | 5% |
|
| Institutional Ownership | 0.0% | 77.3% | 0% |
|
| Float (Mil) | na | 34.7 | na |
|
| Beta | na | 0.86 | na |
|
| Avg Daily Volume (000s) | 10,471 | 266 | 97% |
|
| Price Change (52-week) |
(6.7%) | 60.7% | 40% |
|
| Growth | ADVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | na | (5.8%) | na |
|
| EPS (5yr) | na | 10.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (16.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ADVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $152 | na |
|
| Net Income (TTM) (Mil) | $5 | ($11) | 43% |
|
| EPS (TTM) | $4.665 | ($0.500) | 86% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($2) | 27% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $22 | 0% |
|
| Enterprise Value (Q1) (Mil) | $5 | $304 | 5% |
|
| Valuation | ADVB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.51 | 2.88 | 39% |
|
| P/E | 2.4 | 30.5 | 2% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | ADVB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 59.1% | na |
|
| Net Margin | na | (7.7%) | na |
|
| ROA | 55.8% | (13.7%) | 99% |
|
| ROE | 79.2% | (15.9%) | 95% |
|
| Liabilities to Assets | 13.5% | 44.9% | 8% |
|
| F-Score | 2 | 4 | 7% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Fundamental Rule of Thumb Screen
Factors: Value
An old value screen combining the P/E ratio, dividend yield, and an adjusted return on equity that's still applicable in today's market.
| Performance Since Inception: | 7.0% |
| +/- S&P 500: | -0.5 |
